BACKGROUND: CD40 has been shown to be a functional activation antigen on a variety of cell types involved in immune responses. As intestinal fibroblasts and myofibroblasts may play a role during mucosal inflammation, we investigated the functional consequences of CD40 induction in primary cultures of human colonic fibroblasts. METHODS: Primary colonic lamina propria fibroblasts (PCLF) were isolated from endoscopic biopsies and surgical specimens. Cultures were used between passages 3 and 9. CD40 surface display was determined by FACS analysis and mRNA expression by reverse transcription-polymerase chain reaction. Secretion of cytokines was determined by ELISA. Nuclear factor kappaB (NFkappaB) activation was shown by electrophoretic mobility shift assay (EMSA). RESULTS: After priming with interferon gamma (IFN-gamma) (200 U/ml) for 72 hours, five of eight tested PCLF cultures showed induction of CD40 surface display (up to 10-fold). Induction of CD40 mRNA expression was demonstrated by semiquantitative polymerase chain reaction. In the responder-PCLF cultures, IFN-gamma alone caused a 1.5-5-fold increase in interleukin (IL)-8 secretion. Addition of 1 ng/ml CD40L was sufficient to achieve a further increase in IL-8, IL-6, or monocyte chemotactic protein 1 (MCP-1) secretion (2.5-18-fold of controls). Incubation with CD40L alone without priming with IFN-gamma had no effect. The proteasome inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (ALLN 100 microM) reduced IFN-gamma/CD40L mediated cytokine induction, suggesting participation of NFkappaB, which was directly demonstrated by EMSA. CD4+ T cells induced MCP-1 secretion by PCLF, which was prevented by addition of an excess of CD40-IgG fusion protein. CD40 expression on PCLF could also be demonstrated in vivo by immunohistochemistry. CONCLUSION: The CD40-CD40L pathway augments mucosal inflammatory responses via mucosal PCLF. CD40-CD40L mediated T cell/PCLF interactions could play an important role during intestinal mucosal inflammation.
BACKGROUND:CD40 has been shown to be a functional activation antigen on a variety of cell types involved in immune responses. As intestinal fibroblasts and myofibroblasts may play a role during mucosal inflammation, we investigated the functional consequences of CD40 induction in primary cultures of human colonic fibroblasts. METHODS:Primary colonic lamina propria fibroblasts (PCLF) were isolated from endoscopic biopsies and surgical specimens. Cultures were used between passages 3 and 9. CD40 surface display was determined by FACS analysis and mRNA expression by reverse transcription-polymerase chain reaction. Secretion of cytokines was determined by ELISA. Nuclear factor kappaB (NFkappaB) activation was shown by electrophoretic mobility shift assay (EMSA). RESULTS: After priming with interferon gamma (IFN-gamma) (200 U/ml) for 72 hours, five of eight tested PCLF cultures showed induction of CD40 surface display (up to 10-fold). Induction of CD40 mRNA expression was demonstrated by semiquantitative polymerase chain reaction. In the responder-PCLF cultures, IFN-gamma alone caused a 1.5-5-fold increase in interleukin (IL)-8 secretion. Addition of 1 ng/ml CD40L was sufficient to achieve a further increase in IL-8, IL-6, or monocyte chemotactic protein 1 (MCP-1) secretion (2.5-18-fold of controls). Incubation with CD40L alone without priming with IFN-gamma had no effect. The proteasome inhibitor N-acetyl-leucinyl-leucinyl-norleucinal (ALLN 100 microM) reduced IFN-gamma/CD40L mediated cytokine induction, suggesting participation of NFkappaB, which was directly demonstrated by EMSA. CD4+ T cells induced MCP-1 secretion by PCLF, which was prevented by addition of an excess of CD40-IgG fusion protein. CD40 expression on PCLF could also be demonstrated in vivo by immunohistochemistry. CONCLUSION: The CD40-CD40L pathway augments mucosal inflammatory responses via mucosal PCLF. CD40-CD40L mediated T cell/PCLF interactions could play an important role during intestinal mucosal inflammation.
Authors: N Sawada-Hase; T Kiyohara; J Miyagawa; H Ueyama; H Nishibayashi; Y Murayama; T Kashihara; M Nakahara; Y Miyazaki; S Kanayama; R Nezu; Y Shinomura; Y Matsuzawa Journal: Am J Gastroenterol Date: 2000-06 Impact factor: 10.864
Authors: Z Liu; K Geboes; S Colpaert; L Overbergh; C Mathieu; H Heremans; M de Boer; L Boon; G D'Haens; P Rutgeerts; J L Ceuppens Journal: J Immunol Date: 2000-06-01 Impact factor: 5.422
Authors: Y P De Jong; M Comiskey; S L Kalled; E Mizoguchi; R A Flavell; A K Bhan; C Terhorst Journal: Gastroenterology Date: 2000-09 Impact factor: 22.682
Authors: G Rogler; C M Gelbmann; D Vogl; M Brunner; J Schölmerich; W Falk; T Andus; K Brand Journal: Scand J Gastroenterol Date: 2001-04 Impact factor: 2.423
Authors: T Whittall; Y Wang; C G Kelly; R Thompson; J Sanderson; M Lomer; S Y Soon; L A Bergmeier; M Singh; T Lehner Journal: Clin Exp Immunol Date: 2006-03 Impact factor: 4.330
Authors: D C Baumgart; S Thomas; I Przesdzing; D Metzke; C Bielecki; S M Lehmann; S Lehnardt; Y Dörffel; A Sturm; A Scheffold; J Schmitz; A Radbruch Journal: Clin Exp Immunol Date: 2009-09 Impact factor: 4.330
Authors: S Tanaka; A Tatsuguchi; S Futagami; K Gudis; K Wada; T Seo; K Mitsui; M Yonezawa; K Nagata; S Fujimori; T Tsukui; T Kishida; C Sakamoto Journal: Gut Date: 2005-08-05 Impact factor: 23.059
Authors: Erin F Gillespie; Nupur Raychaudhuri; Konstantinos I Papageorgiou; Stephen J Atkins; Ying Lu; Laya K Charara; Tünde Mester; Terry J Smith; Raymond S Douglas Journal: Invest Ophthalmol Vis Sci Date: 2012-11-21 Impact factor: 4.799